ReportWire

Tag: UC San Diego

  • The Rocket Propulsion Laboratory at UC San Diego and Valworx Announce a Partnership for Liquid Bipropellant Rocket Project

    Valworx, Inc., a leading supplier of actuated valves and controls, has partnered with The Rocket Propulsion Laboratory at UC San Diego to develop the next generation of

    “The Rocket Propulsion Laboratory at UC San Diego strives to provide challenging and exciting projects for students to develop their technical knowledge, leadership abilities, and hands-on skills. Our work seeks to improve the technical skills and diversity of the next generation of emerging talent, as well as continuously push the limits of what an undergraduate rocketry team can do.” said Daniel Carrillo, President, RPL @ University of California, San Diego.

    “Through their sponsorship and support, Valworx has provided us with components that will enable us to validate rocket component characteristics such as max. pressure and flow rate, as well as the discharge coefficient of injectors. The valves will also be used as a basis for theoretical actuation mechanisms that will be integrated into future rockets or test stands and as a basis for throttling experiments to control the flow rate within a future rocket system”, said Steven Smith, Phoenix Chief Engineer.

    “The Rocket Propulsion Laboratory program continues to build on prior innovations, and we’re excited to play a part in helping the next generation of aerospace leaders push the boundaries of student-led rocketry,” said Kurt Naas, President of Valworx.

    About Valworx

    Established in 1991, Valworx is a leading supplier of actuated valves and controls in stainless, brass, PVC, and sanitary ball and butterfly valves. They offer free shipping on orders over $99, free lifetime technical support, extensive online documentation and a generous return policy. All products are backed by a comprehensive one-year warranty.

    Valworx-brand products are known, trusted and preferred by tens of thousands of users worldwide, meeting their customers’ expectations for price, delivery, and performance.

    For more info, visit https://www.valworx.com, follow us on Twitter (@valworxvalves), and https://www.facebook.com/valworxvalves.

    About the Rocket Propulsion Laboratory at UC San Diego

    RPL’s goal is to provide student-led research opportunities for students passionate about space exploration. We strive to provide challenging and exciting projects for students to develop their technical knowledge, leadership abilities, and hands-on skills.

    For more information, visit https://www.rocketproplab.org/.

    Contact Information

    Caroline Crowe
    Strategic Account Manager
    sales@valworx.com
    704-987-9803

    Source: Valworx, Inc.

    Source link

  • The Latest On Medical Marijuana And Migraines

    They can destroy a day in seconds…but can marijuana help with migraines?

    They can upend sometimes day when they arrive and devastate lives over the long term…so what is the latest on medical marijuana and migraines? A wave of fresh research is casting new light on the potential of medical marijuana as a treatment for migraines, the debilitating neurological condition affecting about 15% of people globally, or nearly 1 billion individuals. In the U.S., the lifetime incidence stands at roughly 43% for women and 18% for men.

    RELATED: 5 Ways Medical Marijuana Can Help You Deal With Chronic Pain

    Migraine recognition remains crucial for timely intervention. Classic signs include a pulsating, moderate-to-severe headache, typically unilateral, often accompanied by nausea, and hypersensitivity to light (photophobia) and sound (phonophobia). Attacks may last from 4 to 72 hours, and many sufferers go through prodromal symptoms—mood changes, fatigue, or neck pain—before the headache phase.

    In a landmark placebo-controlled clinical trial presented at the 2025 American Headache Society Annual Meeting, researchers at UC San Diego demonstrated vaporizing a precise mixture of 6% THC and 11% CBD leads to significant migraine relief:

    • 67.2% of participants experienced pain relief within 2 hours, compared to ~46.6% receiving placebo.
    • 34.5% reached complete pain freedom, versus 15.5% with placebo.
    • Benefits were sustained for 24 hours for pain relief, and 48 hours for relief from their most bothersome symptoms, including light or sound sensitivity.

    Investigators highlighted the importance of controlled, infrequent dosing—limiting use to under 10 times per month—to avoid medication overuse headaches (MOH) and reduce risks of psychoactive effects.

    A systematic review covering nearly 2,000 migraine patients revealed medical cannabis reduced monthly headache frequency from 10.4 to 4.6 days—a remarkable ~56% drop. It also alleviated associated nausea and vomiting, with effects comparable to amitriptyline in reducing frequency (~40%).

    RELATED: Immersive Events Redefine Millennial Nights

    Survey-based studies echo these findings:

    • In one registry, patients reported inhaled cannabis halved migraine severity, though effectiveness waned over time.
    • Another review confirmed medical marijuana significantly reduces both the length and frequency of migraines, with no severe adverse events noted (cannabisclinicians.org).

    Despite promising outcomes, more research is needed. A retrospective study found cannabis use increased the prevalence of medication overuse headache (MOH)—patients using cannabis were nearly 6 times more likely to develop MOH compared to non-users. Mild side effects—such as drowsiness, lightheadedness, or cognitive blips—occurred in up to 43.75% of users, particularly with oral forms.

    Amy Hansen

    Source link

  • We Have No Drugs to Treat the Deadliest Eating Disorder

    We Have No Drugs to Treat the Deadliest Eating Disorder

    In the 1970s, they tried lithium. Then it was zinc and THC. Anti-anxiety drugs had their turn. So did Prozac and SSRIs and atypical antidepressants. Nothing worked. Patients with anorexia were still unable to bring themselves to eat, still stuck in rigid thought patterns, still chillingly underweight.

    A few years ago, a group led by Evelyn Attia, the director of the Center for Eating Disorders at New York Presbyterian Hospital and the New York State Psychiatric Institute, tried giving patients an antipsychotic drug called olanzapine, normally used to treat schizophrenia and bipolar disorder, and known to cause weight gain as a side effect. Those patients in her study who were on olanzapine increased their BMI a bit more than others who were taking a placebo, but the two groups showed no difference in their cognitive and psychological symptoms. This was the only medication trial for treating anorexia that has shown any positive effect at all, Attia told me, and even then, the effects were “very modest.”

    Despite nearly half a century of attempts, no pill or shot has been identified to effectively treat anorexia nervosa. Anorexia is well known to be the deadliest eating disorder; the only psychiatric diagnosis with a higher death rate is opioid-use disorder. A 2020 review found people who have been hospitalized for the disease are more than five times likelier to die than their peers without it. The National Institutes of Health has devoted more than $100 million over the past decade to studying anorexia, yet researchers have not found a single compound that reliably helps people with the disorder.

    Other eating disorders aren’t nearly so resistant to treatment. The FDA has approved fluoxetine (a.k.a. Prozac) to treat bulimia nervosa and binge-eating disorder (BED); doctors prescribe additional SSRIs off-label to treat both conditions, with a fair rate of success. An ADHD drug, Vyvanse, was approved for BED within two years of the disorder’s official recognition. But when it comes to anorexia, “we’ve tried, I don’t know, eight or 10 fundamentally different kinds of approaches without much in the way of success,” says Scott Crow, an adjunct psychology professor at the University of Minnesota and the vice president of psychiatry for Accanto Health.

    The discrepancy is puzzling to anorexia specialists and researchers. “We don’t fully understand why medications work so differently in this group, and boy, do they ever work differently,” Attia told me. Still, experts have some ideas. Over the past few decades, they have been learning about the changes in brain activity that accompany anorexia. For example, Walter Kaye, the founder and executive director of the Eating Disorders Program at UC San Diego, told me that the neurotransmitters serotonin and dopamine, both of which are involved in the brain’s reward system, seem to act differently in anorexia patients.

    Perhaps some underlying differences in brain chemistry and function play a role in anorexia patients’ extreme aversion to eating. Or perhaps, the experts I spoke with suggested, these brain changes are at least in part a result of patients’ malnourishment. People with anorexia suffer from many effects of malnutrition: Their bones are more brittle; their brain is smaller; their heart beats slower; their breath comes shorter; their wounds fail to heal. Maybe their neurons respond differently to psychoactive drugs too.

    Psychiatrists have found that many patients with anorexia don’t improve with treatment even when medicines are prescribed for conditions other than their eating disorder. If an anorexia patient also has anxiety, for example, taking an anti-anxiety drug would likely fail to relieve either set of symptoms, Attia told me. “Time and again, investigators have found very little or no difference between active medication and placebo in randomized controlled trials,” she said. The fact that fluoxetine seems to help anorexia patients avoid relapse—but only when it’s given after they’ve regained a healthy weight—also supports the notion that malnourished brains don’t respond so well to psychoactive medication. (In that case, the effect might be especially acute for people with anorexia nervosa, because they tend to have lower BMIs than people with other eating disorders.)

    Why exactly this would be true remains a mystery. Attia noted that proteins and certain fats have been shown to be crucial for brain function; get too little of either, and the brain might not metabolize drugs in expected ways. Both she and Kaye suggested a possible role for tryptophan, an amino acid that humans get only from food. Tryptophan is converted into serotonin (among other things) when we release insulin after a meal, Kaye said, but in anorexia patients, whose insulin levels tend to be low, that process could end up off-kilter. “We suspect that that might be the reason why [SSRIs] don’t work very well,” he said, though he emphasized that the theory is very speculative.

    In the absence of meaningful pharmacologic intervention, doctors who treat anorexia rely on methods such as nutrition counseling and psychotherapy. But even non-pharmaceutical interventions, such as cognitive behavioral therapy, are more effective at treating bulimia and binge-eating disorder than anorexia. Studies from around the world have shown that as many as half of people with anorexia relapse.

    Colleen Clarkin Schreyer, a clinical psychologist at Johns Hopkins University, sees both patients with anorexia nervosa and those with bulimia nervosa, and told me that the former can be more difficult to treat—“but not just because of the fact that we don’t have any medication to help us along. I often find that patients with anorexia nervosa are more ambivalent about making behavior change.” Bulimia patients, she said, tend to feel shame about their condition, because binge eating is stigmatized and, well, no one likes vomit. But anorexia patients might be praised for skipping meals or rapidly losing weight, despite the fact that their behaviors can be just as dangerous over the long term as binging and vomiting.

    Researchers are still trying to find substances that can help anorexia patients. Crow told me that case studies testing a synthetic version of leptin, a naturally occurring human hormone, have produced interesting data. Meanwhile, some early research into using psychedelics, including ketamine, psilocybin, and ayahuasca, suggests that they may relieve some symptoms in some cases. But until randomized, controlled trials are conducted, we won’t know whether or how well any psychedelic really works. Kaye is currently recruiting participants for such a study of psilocybin, which is planned to have multiple sites in the U.S. and Europe.

    Pharmaceutical companies just don’t seem that enthusiastic about testing treatments for anorexia, Crow said. “I think that drug makers have taken to heart the message that the mortality is high” among anorexia patients, he told me, and thus avoid the risk of having deaths occur during their clinical trials. And drug development isn’t the only area where the study of anorexia has fallen short. Research on eating disorders tends to be underfunded on the whole, Crow said. That stems, in part, from “a widely prevailing belief that this is something that people could or should just stop … I wish that were how it works, frankly. But it’s not.”

    Rachel Gutman-Wei

    Source link

  • Can Gravity Make People Sick?

    Can Gravity Make People Sick?

    Bad things happen to a human body in zero gravity. Just look at what happens to astronauts who spend time in orbit: Bones disintegrate. Muscles weaken. So does immunity. “When you go up into space,” says Saïd Mekari, who studies exercise physiology at the University of Sherbrooke, in Canada, “it’s an accelerated model of aging.” Earthbound experiments mimicking weightlessness have revealed similar effects. In the 1970s, Russian scientists immersed volunteers in bathtubs covered in a large sheet of waterproof fabric, enabling them to float without being wet. In some of these studies, which lasted up to 56 days, subjects developed serious heart problems and struggled to control their posture and leg movements.

    Weightlessness hurts us because our bodies are fine-tuned to gravity as we experience it here on Earth. It tugs at us from birth to death, and still our intestines stay firmly coiled in their stack, blood flows upward, and our spine is capable of holding up our head. Unnatural contortions can throw things off: People have died from hanging upside down for too long. But as a general rule, the constant push of g-force on our body is a part of life that we rarely notice.

    Or at least, that’s what scientists have always thought. But there is another possibility: that gravity itself is making some people sick. A new, peer-reviewed theory suggests that the body’s relationship with gravity can go haywire, causing a disorder that has long been a troubling mystery: irritable bowel syndrome.

    This is a rogue idea that is far from widely accepted, though one that at least some experts say can’t be dismissed outright. IBS is a very common ailment, affecting up to an estimated 15 percent of people in the United States, and the symptoms can be brutal. People who have IBS experience abdominal pain and gas, feel bloated, and often have diarrhea, constipation, or both. But no exact cause of IBS has been pinned down. There’s evidence behind many competing theories, such as early-life stress, diet, and even gut infections, but none have emerged as the sole explanation. That is a problem for patients—it’s difficult to treat a condition when you don’t know what to target.

    Brennan Spiegel, a gastroenterologist at Cedars-Sinai Medical Center, in Los Angeles, has a different idea: People with IBS are hypersensitive to gravity as a result of any number of factors—stress, weight gain, a change in the gut microbiome, bad sleep patterns, or another behavior or injury. The idea came to him after watching a relative confined to a nursing-home bed develop classic symptoms of IBS. “We’re upright organisms,” he told me. “We’re not really supposed to be lying flat for that long.” The hypothesis, published late last year in The American Journal of Gastroenterology, is just that, a hypothesis. Spiegel hasn’t conducted any experiments or patient surveys that point to a “mismatch” in our body’s reaction to gravity as the cause of IBS, though the mechanics are all based in firm science. But part of what makes the theory so alluring is that it might encompass all of the other conventional explanations for the disease. “It’s meant to be a new way of thinking about old ideas,” he said.

    So exactly how would someone’s relationship with gravity get off-kilter? Consider serotonin, a chemical that carries messages from the brain to the body. Spiegel sees serotonin as an “anti-gravity substance” because of the role it plays in so many important bodily functions influenced by g-force, such as blood flow. Serotonin can cause blood vessels to narrow, slowing circulation. It can make certain muscles contract or relax. It’s also crucial to digestion, helping with bowel function, getting rid of irritating foods, and regulating how much we eat. Without serotonin, gravity would turn our intestines into a “flaccid sac,” Spiegel writes. Because 95 percent of the body’s serotonin is produced in the gut, if levels spike or plummet from factors such as stress, then the chemical’s possible handling of gravity would be thrown into chaos, affecting digestion. The result, he theorizes, is IBS.

    Other parts of our body that respond to gravity can also be in on the problem. We are hardwired to react negatively to situations in which the pull of gravity might harm us; walk to the edge of a cliff and your body will tell you something. The amygdala in our brain is key to fear responses, and stress of various kinds can cause it to go into overdrive. Spiegel thinks that when stress taxes the amygdala, a person begins overreacting to potential threats, including from gravity. The digestive issues that make up IBS are a manifestation of that overreaction. Sure enough, people with IBS have been shown to have a hyperactive amygdala.

    That is hardly anything close to proof. The thought that this painful and prolonged condition could be a gravity disorder is a major stretch, relying on a renegade interpretation of basic biology. “People just think I’m crazy,” Spiegel said. Many of his fellow doctors are not sold on the idea. The gravity hypothesis is another in a long parade of unconvincing theories about IBS, Emeran Mayer, a gastroenterologist at UCLA, told me. He’s heard them all: “It doesn’t exist; it’s a hysterical trait of neurotic housewives; it’s abnormal electrical activity in the colon.” He added, “I don’t think there’s any other disease that has gone through these peaks of attention-grabbing new theories.”

    Spiegel’s idea has clear holes. If a faulty reaction to gravity triggers IBS, says David C. Kunkel, a gastroenterologist at UC San Diego, then you would expect to see higher rates of IBS among populations living at sea level versus at high altitudes, where g-force is slightly weaker. But that doesn’t seem to be the case: About a quarter of Peruvians live high in the mountains and most Icelanders live at sea level, yet both countries have high rates of IBS. Likewise, IBS rates appear to decrease with age, “which would not be expected if the disease was caused by a constant gravitational force,” Kunkel told me.

    Spiegel is aware that the gravity hypothesis has little support in the field and no proof. But the gravity hypothesis has some logic behind it. The fact that the weightlessness of space travel can drastically change the body lends credence to the idea that other shifts in our relationship to gravity could do the same, says Declan McCole, a biomedical scientist at UC Riverside.

    And the gut may be particularly sensitive to gravity changes. McCole has found that weightlessness made epithelial cells—which line the gut and stop invaders from entering the body—easier to evade. So if our internal chemistry can change in a way that makes us hypersensitive to gravity, then, to McCole, it stands to reason that such a shift could hit the gut hard. He’s less sure of whether that hypersensitivity exists. If it does, then why haven’t we identified any chemicals that help handle gravity, as we have for fear or sex drive or hunger? That molecule may indeed turn out to be serotonin, but right now there’s no proof.

    The gravity hypothesis really matters only if it is meaningful for people with IBS. And that’s not guaranteed. Tying the very real pain of IBS to such a fantastical idea may seem closer to mythology than medicine, leaving patients feeling dismissed or belittled. Or they may throw up their hands in despair and prepare for a lifetime of pain: If the immovable force of gravity is the enemy, then why bother fighting?

    But if there is some truth to it, then the hypothesis could also provide a possible starting place for treatments. Some of Spiegel’s suggestions are already common, such as weight loss and medications that decrease serotonin, but he also advocates for some gravity-specific therapies. “I do talk about it with my patients,” Spiegel said. “I recommend certain yoga poses; I recommend tilt tables.” People who have IBS may balk at his more radical ideas, such as moving to a higher altitude or farther from the equator.

    The gravity hypothesis may never be anything more than a hypothesis. We have a long way to go before truly knowing whether the human body can develop a hypersensitivity to gravity that can make us ill, or whether some of us are better equipped to handle gravity than others. But the weight of evidence is enough to make us think twice before ignoring the idea that our body’s relationship to gravity can go awry—including for those of us not coping with IBS. If gravity might contribute to IBS, why not other ailments too? And then, why can’t it also be harnessed for good? Mekari and his colleagues recently found that lying at a six-degree downward angle sped up response times to cognition tests—pointing to a possible link between gravity and executive functioning. Antigravity treadmills, which help astronauts prepare for weightlessness, are being studied for the treatment of cerebral palsy, Parkinson’s disease, and sports injuries.

    All of these unknowns about gravity can feel haunting. Life on Earth has changed a lot since its first forms appeared about 4 billion years ago, but through it all, gravity has seemingly remained constant—perhaps the single thing that connects every organism that has ever lived. What if there’s still much we have to learn about what it’s doing to us? After all, right now your body is coping with gravity, just as it has been for every other second of your life. Perhaps it would be weirder if gravity wasn’t doing anything to us over time. “Every fiber in our body is straining to manage this force,” Spiegel said. You don’t need to spend 56 days in a bathtub to figure that out.

    Jessica Wapner

    Source link

  • Airplane Toilets Could Catch the Next COVID Variant

    Airplane Toilets Could Catch the Next COVID Variant

    Airplane bathrooms are not most people’s idea of a good time. They’re barely big enough to turn around in. Their doors stick, like they’re trying to trap you in place. That’s to say nothing of the smell. But to the CDC, those same bathrooms might be a data gold mine.

    This month, the agency has been speaking with Concentric, the public-health and biosecurity arm of the biotech company Ginkgo Bioworks, about screening airplane wastewater for COVID-19 at airports around the country. Although plane-wastewater testing had been in the works already (a pilot program at John F. Kennedy International Airport, in New York City, concluded last summer), concerns about a new variant arising in China after the end of its “zero COVID” policies acted as a “catalyst” for the project, Matt McKnight, Ginkgo’s general manager for biosecurity, told me. According to Ginkgo, even airport administrators are getting excited. “There have been a couple of airports who have actually reached out to the CDC to ask to be part of the program,” Laura Bronner, Ginkgo’s vice president of commercial strategies, told me.

    Airplane-wastewater testing is poised to revolutionize how we track the coronavirus’s continued mutations around the world, along with other common viruses such as flu and RSV—and public-health threats that scientists don’t even know about yet. Unlike sewer-wide surveillance, which shows us how diseases are spreading among large communities, airplane surveillance is precisely targeted to catch new variants entering the country from abroad. And unlike with PCR testing, passengers don’t have to individually opt in. (The results remain anonymous either way.) McKnight compares the technique to radar: Instead of responding to an attack after it’s unfolded, America can get advance warning about new threats before they cause problems. As we enter an era in which most people don’t center their lives on avoiding COVID-19, our best contribution to public health might be using a toilet at 30,000 feet.

    Fundamentally, wastewater testing on airplanes is a smaller-scale version of the surveillance that has been taking place at municipal water networks since early 2020: Researchers perform genetic testing on sewage samples to determine how much coronavirus is present, and which variants are included. But adapting the methodology to planes will require researchers to get creative. For one thing, airplane wastewater has a higher solid-to-liquid ratio. Municipal sewage draws from bathing, cooking, washing clothes, and other activities, whereas airplane sewage is “mainly coming from the toilet,” says Kata Farkas, a microbiologist at Bangor University. For a recent study tracking COVID-19 at U.K. airports, Farkas and her colleagues had to adjust their analytical methods, tweaking the chemicals and lab techniques used to isolate the coronavirus from plane sewage.

    Researchers also need to select flights carefully to make sure the data they gather are worth the effort of collecting them. To put it bluntly, not everyone poops on the plane—and if the total number of sampled passengers is very small, the analysis isn’t likely to return much useful data. “The number of conversations we’ve had about how to inconspicuously know how many people on a flight have gone into a lavatory is hysterical,” says Casandra Philipson, who leads the Concentric bioinformatics program. (Concentric later clarified that they do not have plans to actually monitor passengers’ bathroom use.) Researchers ended up settling on an easier metric: Longer flights tend to have more bathroom use and should therefore be the focus of wastewater testing. (Philipson and her colleagues also work with the CDC to test flights from countries where the government is particularly interested in identifying new variants.)

    Beyond those technical challenges, scientists face the daunting task of collaborating with airports and airlines—large companies that aren’t used to participating in public-health surveillance. “It is a tricky environment to work in,” says Jordan Schmidt, the director of product applications at LuminUltra, a Canadian biotech company that tests wastewater at Toronto Pearson Airport. Strict security and complex bureaucracies in air travel can make collecting samples from individual planes difficult, he told me. Instead, LuminUltra samples from airport terminals and from trucks that pull sewage out of multiple planes, so the company doesn’t need to get buy-in from airlines.

    Airplane surveillance seeks to track new variants, not individual passengers: Researchers are not contact-tracing exactly which person brought a particular virus strain into the country. For that reason, companies such as Concentric aren’t planning to alert passengers that COVID-19 was found on their flight, much as some of us might appreciate that warning. Testing airplane sewage can identify variants from around the world, but it won’t necessarily tell us about new surges in the city where those planes land.

    Airplane-wastewater testing offers several advantages for epidemiologists. In general, testing sewage is “dramatically cheaper” and “dramatically less invasive” than nose-swab testing each individual person in a town or on a plane, says Rob Knight, a medical engineering professor at UC San Diego who leads the university’s wastewater-surveillance program. Earlier this month, a landmark report from the National Academies of Sciences, Engineering, and Medicine (which Knight co-authored) highlighted international airports as ideal places to seek out new coronavirus variants and other pathogens. “You’re going to capture people who are traveling from other parts of the world where they might be bringing new variants,” Knight told me. And catching those new variants early is key to updating our vaccines and treatments to ensure that they continue to work well against COVID-19. Collecting more data from people traveling within the country could be useful too, Knight said, since variants can evolve at home as easily as abroad. (XBB.1.5, the latest variant dominating COVID-19 spread in the U.S., is thought to have originated in the American Northeast.) To this end, he told me, the CDC should consider monitoring large train stations or seaports too.

    When wastewater testing first took off during the pandemic, the focus was mostly on municipal facilities, because they could provide data for an entire city or county at once. But scientists have since realized that a more specific view of our waste can be helpful, especially in settings that are crucial for informing public-health actions. For example, at NYC Health + Hospitals, the city’s public health-care system, wastewater data help administrators “see 10 to 14 days in advance if there are any upticks” in coronavirus, flu, or mpox, Leopolda Silvera, Health + Hospitals’ global-health deputy, told me. Administrators use the data in decisions about safety measures and where to send resources, Silvera said: If one hospital’s sewage indicates an upcoming spike in COVID-19 cases, additional staff can be added to its emergency department.

    Schools are another obvious target for small-scale wastewater testing. In San Diego, Rebecca Fielding-Miller directed a two-year surveillance program for elementary schools. It specifically focused on underserved communities, including refugees and low-income workers who were hesitant to seek out PCR testing. Regular wastewater testing picked up asymptomatic cases with high accuracy, providing school staff and parents with “up to the minute” information about COVID-19 spread in their buildings, Fielding-Miller told me. This school year, however, funding for the program ran out.

    Even neighborhood-level surveillance, while not as granular as sampling at a plane, hospital, or school, can provide more useful data than city-wide testing. In Boston, “we really wanted hyperlocal surveillance” to inform placements of the city’s vaccine clinics, testing sites, and other public-health services, says Kathryn Hall, the deputy commissioner at the city’s public-health agency. She and her colleagues identified 11 manhole covers that provide “good coverage” of specific neighborhoods and could be tested without too much disruption to traffic. When a testing site lights up with high COVID-19 numbers, Hall’s colleagues reach out to community organizations such as health centers and senior-living facilities. “We make sure they have access to boosters, they have access to PPE, they understand what’s going on,” Hall told me. In the nearby city of Revere, a similar program run by the company CIC Health showed an uptick in RSV in neighborhood wastewater before the virus started making headlines. CIC shared the news with day-care centers and helped them respond to the surge with educational information and PPE.

    According to wastewater experts, hyperlocal programs can’t usher in a future of disease omnipotence all by themselves. Colleen Naughton, an environmental-engineering professor at UC Merced who runs the COVIDPoops19 dashboard, told me she would like to see communities with no wastewater surveillance get resources to set it up before more funding goes into testing individual buildings or manhole covers. The recent National Academies report presents a future of wastewater surveillance that includes both broad monitoring across the country and testing targeted to places where new health threats might emerge or where certain communities need local information to stay safe.

    This future will require sustained federal funding beyond the current COVID-19 emergency, which is set to expire if the Biden administration does not renew it in April. The United States needs “better and more technology, with a funding model that supports its development,” in order for wastewater’s true potential to be realized, Knight said. Airplane toilets may very well be the best first step toward that comprehensive sewage-surveillance future.

    Betsy Ladyzhets

    Source link